RWA Wealth Partners LLC Purchases New Position in DexCom, Inc. (NASDAQ:DXCM)

RWA Wealth Partners LLC acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,969 shares of the medical device company’s stock, valued at approximately $231,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Allianz SE acquired a new stake in shares of DexCom during the 4th quarter worth about $3,916,000. Allstate Corp bought a new stake in DexCom during the fourth quarter worth about $922,000. DnB Asset Management AS increased its holdings in shares of DexCom by 10.7% during the fourth quarter. DnB Asset Management AS now owns 246,385 shares of the medical device company’s stock worth $19,161,000 after buying an additional 23,914 shares in the last quarter. Level Four Advisory Services LLC raised its stake in shares of DexCom by 1.1% in the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company’s stock valued at $1,026,000 after acquiring an additional 150 shares during the last quarter. Finally, Orion Portfolio Solutions LLC boosted its holdings in shares of DexCom by 692.3% in the 4th quarter. Orion Portfolio Solutions LLC now owns 28,181 shares of the medical device company’s stock worth $2,192,000 after acquiring an additional 24,624 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on DXCM. Morgan Stanley lifted their price objective on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Canaccord Genuity Group lifted their price target on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Cfra Research raised shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Finally, Citigroup increased their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $67.32 on Wednesday. The company has a market capitalization of $26.31 billion, a price-to-earnings ratio of 47.08, a P/E/G ratio of 2.30 and a beta of 1.28. The firm’s 50 day simple moving average is $81.62 and its 200 day simple moving average is $77.11. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $141.99.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling at DexCom

In related news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares of the company’s stock, valued at approximately $7,432,268.76. The trade was a 10.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 105,009 shares of company stock valued at $8,044,178. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.